loader2
Partner With Us NRI

Alkem Laboratories Ltd share Price Today

Company details

4,601.00
4,667.15
2,940.05
4,795.50
6M Return 36.47%
1Y Return 47.38%
Mkt Cap.(Cr) 55,157.13
Volume 197,993
Div Yield 1.08%
OI
-
OI Chg %
-
Volume 197,993

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Alkem Laboratories announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Total Revenue from Operations was Rs 34,402 million, YoY growth of 11.7%
      • India sales were Rs 23,278 million, YoY growth of 5%
      • International sales were Rs 10,542 million, YoY growth of 27.1%
    • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) was Rs 7,467 million, resulting in an EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY.
    • R&D expenses for the quarter were Rs 1,158 million, or 3.4% of total revenue from operations compared to Rs 1,305 million in Q2FY23 at 4.2% of total revenue from operations
    • Profit before tax (PBT) after the exceptional item was Rs 6,480 million, a growth of 61.1% compared to Q2FY23
      • Exceptional item of Rs 577 million debit was on account of impairment of fixed assets
    • Net Profit (after Minority Interest) was Rs 6,205 million, with YoY growth of 87.6%
  • H1FY24:
    • Total Revenue from Operations was Rs 64,079 million, YoY growth of 13.3%
      • India sales were Rs 42,285 million, YoY growth of 5.8%
      • International sales were Rs 20,688 million, YoY growth of 30.2%
    • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) was Rs 11,359 million, resulting in an EBITDA margin of 17.7% vs. 11.6% in H1FY23. EBITDA increased by 72.9% YoY
    • R&D expenses for H1FY24 was Rs 2,360 million, or 3.7% of total revenue from operations compared to Rs 2,625 million in H1FY23 at 4.6% of total revenue from operations
    • Profit before tax (PBT) after the exceptional item was Rs 10,009 million, a growth of 80.6% compared to H1FY23
      • Exceptional item of Rs 577 million debit was on account of impairment of fixed assets
    • Net Profit (after Minority Interest) was Rs 9,073 million, YoY growth of 97.9%

Commenting on the results, Sandeep Singh, Managing Director, Alkem said, " Continuing our trend of improved performance, Q2 builds on the momentum gained in Q1 with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US market and increased operating leverage, resulting in improved EBITDA margins. Domestic growth for the quarter remained subdued due to sporadic monsoon. However, we observed significant traction in the domestic market during the month of September and anticipate continued momentum in the coming quarter. Our international business, both US and Non-US market maintains its robust performance, which was evident in Q1 and continues to flourish. Our biosimilars portfolio is performing impressively, with Enzene’s latest product addition (Ranibizumab), taking the product suite to 7, and witnessing significant traction in the domestic biosimilars market. We are committed to carrying forward the momentum of better operational performance, building on our recent successes."

Result PDF

View Other Company Results

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Alkem Laboratories Ltd Stocks COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 9,045.29 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 16,520.16 27,959.84
LAST 3M 53,623.33 7,912.60
LAST 6M 94,188.00 82,000.34
LAST 12M 161,805.53 123,740.85
Alkem Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Dec 04, 2023 l NSE Announcement

Alkem Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Dec 01, 2023 l NSE Announcement

Alkem Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Nov 30, 2023 l NSE Announcement

Date Action Type Ratio
Aug 10, 2023 Dividend 500
Feb 17, 2023 Dividend 1250
Feb 17, 2023 Dividend 750

Alkem Laboratories Ltd Information

Stock PE (TTM)
36.52
Promoter Holding
56.74%
Book Value
823.1918
ROCE
12.48%
ROE
11.39%
Description
  • Alkem Laboratories Ltd. is a multinational pharmaceutical company based in India. It manufactures and markets pharmaceutical formulations, generics, and nutraceuticals. It was incorporated in 1973, with its headquarters in Mumbai. In the June 2022 quarter, Alkem Laboratories Ltd. recorded a total income of Rs 2,627.79 crore, up 4.93% against Rs 2,504.38 crore in the March 2022 quarter. The company’s market capitalisation on 10 October 2022 stood at Rs 37,957 crore.

    The company is listed on the Bombay Stock Exchange with the code 539523, and on the National Stock Exchange with the code ALKEM.

    Alkem Laboratories Ltd. is a leading player in the branded and generic drugs space. It has a significant brand share in the cardiovascular, anti-diabetic, central nervous system, anti-osteoporosis, immunosuppressants, anti-malarial, and nutraceutical segments. The company leads the Indian market in the pain management and anti-infective segments. Alkem was awarded the 31st rank in India’s Best Companies to Work for in 2022 by the Great Place to Work Institute.

    The company’s shareholding pattern as of 30 June 2022 represented a 57.14% promoter stake, 5.67% foreign institutional investor stake, 14.1% domestic institutional investor stake, and 23.09% public stake. During the June 2022 quarter, promoter holdings increased from 57.13% to 57.14%, mutual fund holdings increased from 7.52% to 7.85%, and FII holdings also increased from 5.41% to 5.67%.

    The company’s board of directors comprise Mr Basudeo N Singh, Mr Sandeep Singh, Mr Mritunjay Singh, Mr Sarvesh Singh, Mr Srinivas Singh, Mr Arun Purwar, Mr Narendra K Aneja, Dr Dheeraj Sharma, Ms Sangeeta K Singh, and Ms Sudha Ravi. The auditors are BSR & Co. LLP. On 30 June 2022, the company recorded a total of 11.96 crore shares outstanding.

    On 10 October 2022, the company’s BSE share price closed at Rs 3,172.80. Alkem Laboratories Ltd.’s NSE share price closed at Rs 3,174.65. The company’s 52-week high share price was Rs 3,990, while the 52-week low for the company’s share price was Rs 2,828. Alkem Laboratories Ltd.’s share gave investors a one-year return of -18.79%.

    The company’s peers in the pharmaceutical sector include Sun Pharmaceutical Industries Ltd., Dr Reddys Laboratories Ltd., Divis Laboratories Ltd., and Cipla Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013

Tel : 91-22-39829999
Email : investors:alkem.com
Website : http://www.alkemlabs.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 539523
NSE Code : ALKEM
Book Closure Date (Month) :
BSE Group : A
ISIN : INE540L01014

FAQ’s on Alkem Laboratories Ltd Shares

You can buy Alkem Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Alkem Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 04, 2023 03:53 PM the closing price of Alkem Laboratories Ltd was ₹ 4,613.15.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 04, 2023 03:53 PM, the market cap of Alkem Laboratories Ltd stood at ₹ 55,157.13.

The latest PE ratio of Alkem Laboratories Ltd as of Dec 04, 2023 03:53 PM is 36.52

The latest PB ratio of Alkem Laboratories Ltd as of Dec 04, 2023 03:53 PM is 0.18

The 52-week high of Alkem Laboratories Ltd is ₹ 4,795.50 while the 52-week low is ₹ 2,940.05

Download Our App

market app
market app